• Title/Summary/Keyword: Ampicillin-Sulbactam

Search Result 57, Processing Time 0.022 seconds

Susceptibilities of Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated from Milk of Bovine Mastitis to Antibiotics Combined with Sulbactam (젖소 유방염에서 분리된 메티실린 내성 황색포도상구균에 대한 항생제와 Sulbactam 병합의 항균효과)

  • Yoo, Jong-Hyun;Han, Hong-Ryul;Park, Hee-Myung
    • Journal of Veterinary Clinics
    • /
    • v.25 no.4
    • /
    • pp.231-235
    • /
    • 2008
  • Various kinds of antibiotic intramammary infusions are used for treatment of bovine mastitis. As antibiotic-resistant bacteria are increased, the therapeutic rate for bovine mastitis is decreased. The goal of this research is to detect significant synergic effects of combination of antibiotics with sulbactam, $\beta$-lactamase inhibitor, on methicilin-resistant Staphylococcus aureus (MRSA). We used 5 strains of MRSA isolated from bovine mastitis with clinical and subclinical signs. All of the bacteria isolated had resistance to oxacillin and showed multi-resistant patterns in the antimicrobial susceptibility tests. Minimal bactericidal concentrations of ampicillin, amoxicillin, cephalexin, ampicillin/sulbactam(2:1), amoxicillin/sulbactam (2:1), and cephalexin/sulbactam (1:1) were measured according to broth microdilution method suggested by National Committee for Clinical Laboratory Standards (NCCLS, M31-A2) to compare the synergic effects of sulbactam combination with each antibiotic alone. Ampicillin and amoxicillin showed synergic antibacterial activity to 4 and 3 respectively in 5 strains of MRSA in combination with sulbactam. This study demonstrates that ampicillin/sulbactam and amoxicillin/sulbactam can be therapeutic choices for mastitis associated with MRSA.

Outcome of High Dose AmpicillinSulbactam and Colistin Combination Therapy for Treating VentilatorAssociated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: a Pilot Study (Carbapenem내성 Acinetobacter baumannii로 인한 인공호흡기연관 폐렴 환아에서 고용량 Ampicillin-Sulbactam 과 Colistin 항균제 병합요법의 치료적 예후: 예비 연구)

  • Jeong, Seong Hee;Kim, Young A;Choi, Go-eun;Park, Su Eun
    • Pediatric Infection and Vaccine
    • /
    • v.27 no.1
    • /
    • pp.45-52
    • /
    • 2020
  • Purpose: This pilot study aimed to evaluate the efficacy of high dose ampicillin-sulbactam and colistin combination therapy for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in the pediatric intensive care unit of Pusan National University Children's Hospital. Methods: We retrospectively reviewed 17 pediatric patients with VAP caused by CRAB from June 2017 to August 2018. Ten (58.8%) patients were treated with high dose ampicillin-sulbactam and colistin combination therapy (combination therapy group), whereas 7 were treated with colistin only or with various combinations with or without colistin (other antibiotics group). Clinical and bacteriological outcomes were compared between the groups. Results: The mean duration of fever after antibiotic use was 1.30±1.70 days in the combination therapy group and 1.71±1.49 days in the other antibiotics group. The mean duration of days for negative conversion of endotracheal aspirate bacterial culture after antibiotic therapy was 3.40±1.71 days in the combination therapy group and 11.80±8.86 days in the other antibiotics group. The mortality rate within 30 days of antibiotic therapy was 1/10 (10%) in the combination therapy group and 3/7 (42.9%) in the other antibiotics group. Conclusions: High dose ampicillin-sulbactam and colistin combination therapy as early antibiotic treatment in VAP caused by CRAB in children could improve clinical outcomes.

Appropriateness of Ampicillin/sulbactam as Prophylactic Antibiotics in Liver Transplantation (간이식 수술 전후 예방적 항생제 ampicillin/sulbactam의 적절성 평가)

  • Kim, Young-Ae;Cho, Yoon-Sook;Kim, Hyang-Sook;Lee, Hye-Sook;Yi, Nam-Joon;Lee, Kwang-Woong;Suh, Kyung-Suk;Lee, Ju-Yeun
    • Korean Journal of Clinical Pharmacy
    • /
    • v.22 no.4
    • /
    • pp.324-329
    • /
    • 2012
  • The most common complication after liver transplantation (LT) is bacterial infection. The incidence of surgical site infections (SSIs) after LT was variable from 8.8%~37%. However, there has been no confirmed guideline in use of prophylactic antibiotics after LT. Ampicillin/sulbactam has been used as main prophylactic antibiotics after LT in Seoul National University Hospital (SNUH) according to the center protocol. The purpose of this study was to determine the incidence and risk factors for SSI after LT and to evaluate the appropriateness of prophylactic antibiotics. A total of 211 patients who underwent LT between July 2008 and June 2010 at SUNH were included. During study period, ampicillin/sulbactam was selected as prophylactic antibiotics in 140 patients (66.4%). A total of 43 patients (20.4%) developed infections and the incidence of SSI was noted in 28 patients (13.2%); 10.0% in ampicillin/sulbactam group and 19.4% in other antibiotics (p=0.049). The most common pathogen of SSI was MRSA (13 episodes, 49.4%). In multivariate analysis, choledochojejunostomy (OR: 7.0; 95% CI, 2.4-20.0) and lower serum albumin (OR: 3.7; 95% CI, 1.1-12.9) were found to be risk factors of SSIs. In conclusion, the incidence of SSIs after LT in this population was similar to those in other studies. Therefore, the prophylactic antibiotics protocol in LT at SNUH seems to be appropriate.

Comparative Activities of CH2150 and Sulbactam as ${\beta}$-Lactamase Inhibitors Against Escherichia coli and Staphylococcus Aureus Resistant to Ampicillin/Sulbactam (암피실린/설박탐에 내성을 갖는 대장균과 포도상구균에 대한 베타-락타메이즈 억제제 CH2150과 설박탐의 항균효과 비교)

  • Park, Su-Hyun;Kim, Hong-Jin;Kim, Ki-Ho
    • YAKHAK HOEJI
    • /
    • v.41 no.1
    • /
    • pp.126-131
    • /
    • 1997
  • To overcome the problems of the resistance to clavulanic acid, many researchers are developing novel inhibitors that are not sensitive to new mutant ${\beta}$-lactamases. In order to evaluate newly synthesized compound CH2150 (Sodium (3S.5R)-6(Z)-[1-{1-(2-{2-benzoxazoly}thioethyl)-l.2,3-txiazol-4-yl}methylene] penicillanate-1,1-dioxide) as a ${\beta}$-lactamase inhibitor, we examined inhibitory activity of CH2150 against ${\beta}$-lactamases of clinical isolates resistant to ampicillin/sulbactam(12 strains of Escherichia coli and 13 strains of Staphylococcus aureus), and compared with that of sulbactam. Nitrocefin was used as substrate for ${\beta}$-lactamases, and the increase of absorbance was measured spectrophotometerically at 482 nm. ${\beta}$-Lactarnase inhibition of CH2150 against ${\beta}$-lactamases was 73 ~ 96% in E. coli and 76 ~ 79% in S. aureus. Comparatively, that of sulbactam was 96 ~ 100% and 96 ~ 100%, respectively. The inhibitory activity of CH2150 was slightly lower than that of sulbactam. The MIC values of ampicillin combined with CH2150 (2:1) for the clinical isolates were 4~512 ${\mu}$g/ml for E. coli and 1.0 ~ 64 ${\mu}$g/ml for S. aureus, whereas 0.5~16 ${\mu}$g/ml for E. coli and 0.25~8 ${\mu}$g/ml for S. aureus when combined with sulbactam (2:1).

  • PDF

Simultaneous determination of ampicillin sodium and sulbactam sodium in powder for injection by HPLC

  • Mai, Xuan-Lan;Pham, Thuy-Vy;Han, Ga-Hyun;Kum, Su-Jin;Woo, Sang-Hoon;Kang, Jong-Seong;Woo, Mi Hee;Na, Dong-Hee;Chun, In-Koo;Kim, Kyeong Ho
    • Analytical Science and Technology
    • /
    • v.32 no.4
    • /
    • pp.147-154
    • /
    • 2019
  • Ampicillin and Sulbactam (2:1, w/w) are combined in formulation to provide broader antibacterial action in treatment of many infections. The development of analytical method for simultaneouly determine these two compounds was difficult because of the differences in their chemical structures and ratio in the formulation. Current published methods still have some limitations. In this study, we developed an alternative high-performance liquid chromatography (HPLC) assay method for simultaneously determination of ampicillin sodium and sulbactam sodium in powder for injection. Method validation of HPLC method was conducted to determine linearity, precision, accuracy, system suitability, robustness. The linearity of the calibration curves in the desired concentration range was good ($r^2$> 0.9994). RSDs of intra-day and inter-day precision obtained were less than 2.00 %. Accuracy was obtained with the recoveries in range of 98.42 % and 101.36 %. As a result of system suitability, RSD of both retention time and the peak area obtained were not more than 1.0 %. The values of plate number were more than 7000 and symmetric factors obtained were 0.8. As intermediate-precision and robustness of the developed assay, it could be expected to become valuable tools for revising the Korean Pharmacopoeia (KP XI).

${\beta}-Lactamase$ Inhibitory Activity and Comparative Activity of 6-Benzothiazole Penicillin Derivatives in Combination with ${\beta}-Lactam$ Antibiotics (6-벤조치아졸 페니실린 유도체의 베타락타마제 효소억제력과 베타락탐항생제 병용시 활성비교)

  • Yoon, Sang-Bae;Im, Chae-Uk
    • YAKHAK HOEJI
    • /
    • v.52 no.4
    • /
    • pp.306-310
    • /
    • 2008
  • In vitro ${\beta}-lactamase$ inhibitory activity of 6-benzothiazole penicillins (1, 2, 3 and 4) was compared with clavulanic acid, sulbactam and tazobactam. The inhibitory activity of exomethylene compounds (3 and 4) was stronger than those of non-exomethylene compounds (1 and 2). The sulfide 3 showed stronger inhibitory activity than sulbactam, clavulanic acid andsimilar to tazobactam against ${\beta}-lactamase$ Type I enzymes. The inhibitory activity of 4 was stronger than those of sulbactam, clavulanic acid and tazobactam against Type III and IV enzymes. The in vitro antimicrobial activity of ampicillin or cefoperazone combined with 3 or 4 was stronger than those of ampicillin or cefoperazone alone against many ${\beta}-lactamase$ producing strains to show that compounds 3 and 4 have some synergistic effect. The synergistic activity of 3 and 4 was comparable to sulbactam in some ${\beta}-lactamase$ producing strains, but it was inferior to tazobactam.

Antimicrobial effects of β-lactamase inhibitor/β-lactam antibiotics on staphylococcal mastitis (Staphylococcus aureus에 의한 유방염에 대한 β-lactamase 저해제/β-lactam계 항균제 치료 효과)

  • Lim, Suk-Kyung;Lim, Jae-Hhyang;Joo, Yi-Seok;Moon, Jin-San;Lee, Ae-Ri;Koh, Hong-Bum
    • Korean Journal of Veterinary Research
    • /
    • v.43 no.1
    • /
    • pp.113-120
    • /
    • 2003
  • The antimicrobial effect of ${\beta}$-lactam antibiotics, which had ${\beta}$-lactamase inhibitor activity, on Staphylococcus aureus isolated from mastitis was investigated in this study. Out of 166 isolates, 99 isolates (59.6%) produced ${\beta}$-lactamase, and 98 isolates of 99 were ${\beta}$-lactamase positive in above $12.5{\mu}g/m{\ell}$ MIC of penicillin. In the providence distribution, ${\beta}$-lactamase production rate of 4 providence, Gangwon, Gyeonggi, Chungcheong, and Jeolla was 100%, 65.7%, 58.8%, and 50.0%, respectively. Antibiotic activities of ${\beta}$-lactam antibiotics against lactamase positive isolates also were investigated. Antimicrobial effects of ampicillin/sulbactam or amoxicillin/clavulanic acid treated group were better than ampicillin or amoxicillin treated group. In antimicrobial effects on intracellular S aureus, there was no difference 1 hour and 4 hour treatment in control, ampicillin, and amoxicillin group, but in 18 hours treatment, ampicillin/sulbactam or amoxicillin/clavulanic acid had a better effect than ampicillin or amoxicillin (p<0.05).

$\beta$-Lactamase Inhibitory Activity and Comparative Activity of 6-Exomethylenepenam Derivatives Combined with $\beta$-Lactam Antibiotics (6-Exomethylenepenam유도체의 베타락타마제 효소억제력과 베타락탐항생제 병용시 활성비교)

  • 임채욱;박희석;정미량;강주성;임철부
    • YAKHAK HOEJI
    • /
    • v.47 no.6
    • /
    • pp.456-460
    • /
    • 2003
  • In vitro $\beta$-lactamase inhibitory activity of 6-exomethylenepenam compounds ( 1, 2, 3, 4 and 5) was compared with clavulanic acid, sulbactam and tazobactam. The inhibitory activity of compound 3 was stronger than those of sulbactam and clavulanic acid against Type I and II enzymes and stronger than tazobactam against Type III, IV, TEM enzymes. The inhibitory activity of 5 was stronger than sulbactam and clavulanic acid against Type I and II enzymes and stronger than tazobactam against Type III, and IV enzymes. The in vitro antimicrobial activity of 3, 4 and 5 combined with ampicillin and cefoperazone was compared with the sulbactam against $\beta$-lactamase producing 27 strains. But, synergistic activity of 3 and 5 was inferior to tazobactam.

[ ${\beta}$ ]-Lactamase Inhibitory Activity and Comparative Activity of 6-Triazole Exomethylenepenam Derivatives Combined with ${\beta}$-Lactam Antibiotics (6-트리아졸 엑소메칠렌펜남 유도체의 베타락타마제 효소억제력과 베타락탐항생제 병용시 활성비교)

  • Im Chaeuk;Oh Jung Suk;Lee Sun Hye;Kim Kyoung Won;Yim Chul Bu
    • YAKHAK HOEJI
    • /
    • v.49 no.1
    • /
    • pp.51-55
    • /
    • 2005
  • In vitro ${\beta}$-lactamase inhibitory activity of 6-triazole exomethylenepenam compounds (1, 2, 3, 4, 5 and 6) was compared with clavulanic acid, sulbactam and tazobactam. The inhibitory activity of 3, 4 and 5 was stronger than those of sulbactam, clavulanic acid and tazobactam against Type IV enzymes. And, inhibitory activity of 3 and 4 was stronger than those of sulbactam, clavulanic acid and tazobactam against Type III enzymes. The in vitro antimicrobial activity of 3, 4 and 5 combined with ampicillin was better than those with sulbactam and with cefoperazone was compared with the sulbactam against ${\beta}$-lactamase producing 27 strains. The synergistic activity of (Z)-form compounds (3 and 5) was better than that of (E)-form compound (4) and sulfone compound (5) was better than sulfide compound (3).

Serotyping and antibiotic susceptibility of Salmonella species from pigs with rectal stricture found in slaughterhouses (도축장 출하 직장협착 돼지에서 분리된 살모넬라균 혈청형 및 항생제 감수성)

  • Jiyeon Kim;Jinju Gwak;Doori Seo;Jaegi Lee;Daewoong Lim;Hana Kim;Jiyeong Park;Jongwoog Choi;Byeongcheol Yoon
    • Korean Journal of Veterinary Service
    • /
    • v.46 no.2
    • /
    • pp.137-145
    • /
    • 2023
  • From November 2021 to October 2022, 151 pigs were discarded due to the suspected salmonellosis, when assessed by antemortem inspection at slaughterhouses in Gwangju. Among them, 85 cases shown with the rectal stricture were confirmed to be infected with Salmonella spp, when assessed by postmortem inspection and Salmonella-oriented culture in the laboratory, accounting for 56.3% of the carcass discard cases. Salmonella spp. were isolated in 58 cases (68.2%) out of 85 total discard cases. As for serotyping of the Salmonella isolates, 28 cases (48.3%) belonged to serogroup B and 28 cases (48.3%) belonged to serogroup C, those were the most frequent isolates, and 2 cases (3.4%) belonged to serogroup E. The most prevalent serotype was Rissen (39.7%), followed by I4,[5],12:i:-(37.9%), Derby (8.6%), Bareilly (5.2%), Infantis (3.4%), Give (3.4%), and Typhimurium (1.7%). The 58 isolates of salmonellae showed resistance to tetracycline (63.8%), chloramphenicol (56.9%), ampicillin (53.4%), and ampicillin-sulbactam (51.7%). S. Rissen showed resistance to chloramphenicol (82.6%), ampicillin (52.2%), ampicillin-sulbactam (52.2%), and tetracyclin (47.8%). S. I4,[5],12:i:-was resistant to tetracycline (90.9%), ampicillin (81.8%), ampicillin-sulbactam (77.3%), and chloramphenicol (59.1%). Among the isoates, S. Bareilly (3 strains), S. Infantis (2 strains), S. Give (2 strains), S. Rissen (3 strains), and S. I4,[5],12:i:- (1 strain) showed no resistance to the tested antimicrobials. As for the prevalence of the antibiotic resistance pattern, AM-SAM-TE-C was the most common, which was shown in 15.5% of S. Rissen. At second, the resistance pattern was occurred as AM-SAM-TE (12.1%) and AM-SAM-CF-CZ-FOX-CTX-NA-TE-C (12.1%), respectively in the case of S. I4,[5],12:i:-.